McCune-Albright Syndrome: Causes, Symptoms & Treatment

What is McCune-Albright Syndrome?

McCune-Albright Syndrome (MAS) is a rare, non-hereditary genetic disorder caused by a somatic mutation in the GNAS1 gene. This mutation occurs spontaneously shortly after fertilization during early embryonic development and therefore affects only a subset of the body´s cells -- a phenomenon known as mosaicism. The condition was first described independently in the 1930s by physicians Donovan McCune and Fuller Albright.

The syndrome is defined by a classic triad of three key features:

• Fibrous dysplasia of bone
• Cafe-au-lait spots on the skin
• Endocrine dysfunction, most notably precocious puberty

Causes and Genetics

McCune-Albright Syndrome is caused by an activating point mutation in the GNAS1 gene, which encodes the alpha subunit of the stimulatory G-protein (Gs-alpha). This mutation leads to constitutive activation of the cAMP signaling pathway in affected tissues, resulting in uncontrolled stimulation of hormone-producing glands and other cell types. Because the mutation arises after fertilization, it is not inherited and occurs sporadically. The clinical presentation varies widely depending on which tissues carry the mutation.

Symptoms

Fibrous Dysplasia

In fibrous dysplasia, normal bone tissue is replaced by abnormal fibrous tissue. This may affect a single bone (monostotic form) or multiple bones (polyostotic form). Common manifestations include:

• Bone pain and skeletal deformities
• Increased risk of fractures
• Leg length discrepancy or hip deformities (shepherd´s crook deformity)
• Involvement of the skull base, potentially causing visual or hearing impairment

Cafe-au-Lait Spots

These flat, light-brown skin lesions have characteristically irregular, jagged borders (described as resembling the coast of Maine) and often follow the lines of Blaschko, which trace the developmental pathways of embryonic skin cells. They typically appear unilaterally and may be present at birth or develop during early childhood.

Endocrine Dysfunctions

Overactivation of hormone-producing glands leads to a variety of endocrine disorders:

• Precocious puberty: The most common endocrine manifestation, especially in girls. Symptoms include early breast development, menstrual bleeding, and growth spurts in infancy.
• Hyperthyroidism: Overactive thyroid causing weight loss, rapid heartbeat, and restlessness.
• Growth hormone excess: Can result in acromegaly, characterized by enlargement of the hands, feet, and facial features.
• Cushing syndrome: Rare; caused by excess cortisol production from the adrenal glands.
• Hypophosphatemia: Impaired phosphate regulation affecting bone metabolism.

Diagnosis

The diagnosis of McCune-Albright Syndrome is typically made clinically when at least two of the three classic features are present. Diagnostic workup may include:

• Imaging: X-ray, MRI, or CT scans to assess fibrous bone dysplasia
• Hormone panels: Blood and urine tests evaluating endocrine function (e.g., LH, FSH, estrogen, cortisol, IGF-1, thyroid hormones)
• Genetic testing: Detection of the GNAS1 mutation; however, a negative result does not rule out the diagnosis, as the mutation may only be detectable in affected tissues
• Bone scintigraphy: To assess the extent of skeletal involvement
• FGF-23 levels: Measured when renal phosphate wasting is suspected

Treatment

There is currently no curative treatment for McCune-Albright Syndrome. Management is symptomatic and requires a multidisciplinary approach:

Fibrous Dysplasia

• Bisphosphonates (e.g., pamidronate, zoledronic acid): Help reduce bone pain and improve bone density
• Orthopedic interventions: Surgery to stabilize fracture-prone bones or correct deformities
• Phosphate supplementation: When renal phosphate loss is confirmed

Endocrine Dysfunctions

• Precocious puberty: Treated with aromatase inhibitors (e.g., letrozole, anastrozole) or selective estrogen receptor modulators (SERMs) such as tamoxifen
• Hyperthyroidism: Managed with antithyroid drugs, radioiodine therapy, or thyroid surgery
• Growth hormone excess: Treated with somatostatin analogues or GH receptor antagonists
• Cushing syndrome: Medical inhibition of cortisol production or surgical removal of the affected adrenal gland

Ongoing Care

Regular follow-up with an experienced multidisciplinary team -- including endocrinologists, orthopedic surgeons, dermatologists, and neurologists as needed -- is essential. Patients with skull base involvement should undergo routine ophthalmological and audiological assessments.

Prognosis

The prognosis varies considerably depending on the severity and extent of the disease. Mild forms with isolated bone involvement can often be well managed. Severe cases with extensive fibrous dysplasia, multiple endocrine disorders, or significant craniofacial involvement require intensive, lifelong medical care. With appropriate treatment, a normal life expectancy is achievable in many patients.

References

1. Boyce, A. M. & Collins, M. T. (2020). Fibrous Dysplasia/McCune-Albright Syndrome. In: GeneReviews. NCBI Bookshelf. National Library of Medicine.
2. Dumitrescu, C. E. & Collins, M. T. (2008). McCune-Albright syndrome. Orphanet Journal of Rare Diseases, 3(1), 12. doi:10.1186/1750-1172-3-12.
3. World Health Organization (WHO). Rare Diseases. https://www.who.int/news-room/fact-sheets/detail/rare-diseases